Renal Aspects and Enzyme Replacement Therapy of Fabry Disease

Ane Claudia Fernandes Nunes1, Elvino Jose Guardao Barros2, Virgilio Pimentel Delgado3 and Alvimar Goncalves Delgado4 1Laboratory of Cellular, Genetic and Molecular Nephrology (LIM-29) Division of Nephrology, Sao Paulo University Medical School University of Sao Paulo, Sao Paulo/ 2Service of Nephrology, Clinical Hospital of Porto Alegre Federal University of Rio Grande do Sul, Porto Alegre 3Service of Nephrology, Clementino Fraga Filho Hospital Federal University of Rio de Janeiro, Rio de Janeiro Federal Hospital of Bonsucesso, Rio de Janeiro 4Service of Nephrology, Clementino Fraga Filho Hospital Federal University of Rio de Janeiro, Rio de Janeiro Brazil

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  2011-11-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.5772/24264
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Enzyme replacement therapy.

  2019cited by this paper
• Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry ' s disease

  2017cited by this paper
• Enzyme Replacement Therapy

  2010cited by this paper
• Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data.

  2009cited by this paper
• Kidney Function and 24-Hour Proteinuria in Patients with Fabry Disease during 36 Months of Agalsidase Alfa Enzyme Replacement Therapy: A Brazilian Experience

  2009cited by this paper
• Enzyme Replacement Therapy for Fabry Disease

  2009influential reference
• Fabry Disease in Hemodialysis Patients in Southern Brazil: Prevalence Study and Clinical Report

  2008cited by this paper
• Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease.

  2007cited by this paper
• [Fabry disease in childhood].

  2007cited by this paper
• Agalsidase-Beta Therapy for Advanced Fabry Disease

  2007influential reference
• Treatment of Fabry Disease: Outcome of a Comparative Trial with Agalsidase Alfa or Beta at a Dose of 0.2 mg/kg

  2007cited by this paper
• Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study.

  2005cited by this paper
• Significance of screening for Fabry disease among male dialysis patients

  2005cited by this paper
• Fabry disease: diagnosis and management, with emphasis on the renal manifestations

  2005cited by this paper
• Results of a nationwide screening for Anderson-Fabry disease among dialysis patients.

  2004cited by this paper
• Fabry disease in childhood.

  2004cited by this paper
• Long-term safety and efficacy of enzyme replacement therapy for Fabry disease.

  2004cited by this paper
• Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype.

  2003influential reference
• alpha-Galactosidase A deficiency in Dutch patients on dialysis: a critical appraisal of screening for Fabry disease.

  2003influential reference
• Recombinant Enzyme Therapy for Fabry Disease: Absence of Editing of Human α-Galactosidase A mRNA

  2003cited by this paper
• Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy

  2003cited by this paper
• How to improve the early diagnosis of Fabry's disease?

  2003cited by this paper
• Fabry Disease , an UnderRecognized Multisystemic Disorder : Expert Recommendations for Diagnosis , Management , and Enzyme Replacement Therapy

  2003cited by this paper
• The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents

  2003cited by this paper
• Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.

  2002cited by this paper
• Advances in the management of Anderson–Fabry disease:enzyme replacement therapy

  2002cited by this paper
• UvA-DARE ( Digital Academic Repository ) Recombinant enzyme therapy for Fabry disease : absence of editing of human alpha-galactosidase A mRNA

  2002cited by this paper
• Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy

  2002cited by this paper
• Renal pathology in Fabry disease.

  2002influential reference
• Patients with Fabry disease on dialysis in the United States.

  2002influential reference
• A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies.

  2001cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Enzyme replacement therapy in Fabry disease: a randomized controlled trial.

  2001influential reference
• Fabry disease: enzymatic diagnosis in dried blood spots on filter paper.

  2001cited by this paper
• α-Galactosidase A deficiency. Fabry disease

  2001cited by this paper
• Infusion of α-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

  2000cited by this paper
• Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.

  2000cited by this paper
• The role of the podocyte in glomerulosclerosis.

  1999cited by this paper
• Kidney involvement in Anderson-Fabry disease.

  1997cited by this paper
• An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

  1995cited by this paper
• The neurological complications of Anderson-Fabry disease (alpha-galactosidase A deficiency)--investigation of symptomatic and presymptomatic patients.

  1990cited by this paper
• Natural history and treatment of uremia secondary to Fabry's disease: an European experience.

  1987cited by this paper
• Early renal changes in hemizygous and heterozygous patients with Fabry's disease.

  1978cited by this paper
• Ceramide trihexosidosis (fabry's disease) without skin lesions.

  1971cited by this paper

• No citing papers are available for this paper.